Close

Fusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT Medical Collaboration Nov 16, 2023 06:45AM
Fusion Pharmaceuticals (FUSN) and BWXT (BWXT) Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies Jan 5, 2023 05:01PM
Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies Jan 5, 2023 05:00PM
Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies Jan 5, 2023 05:00PM
Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development Jan 10, 2022 04:30PM


Aug 12, 2021 04:05PM Fusion Pharmaceuticals and TRIUMF Announce Expanded R&D Collaboration for Actinium Supply Production
Dec 16, 2020 09:00AM TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope
Dec 16, 2020 09:00AM TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope
Nov 2, 2020 07:08AM Fusion Pharma (FUSN) Announces Collaboration with AstraZeneca (AZN) to Develop and Commercialize Next-Generation Radiopharmaceuticals and Combination Therapies
Nov 2, 2020 07:00AM Fusion Pharmaceuticals Announces Collaboration with AstraZeneca to Develop and Commercialize Next-Generation Radiopharmaceuticals and Combination Therapies